An Innovative Approach to HER2 Classification
HER2Complete™
Paige currently holds CE-IVD and UKCA marks for HER2Complete™, a clinical AI software designed to identify patients with breast cancer whose tumors have expressions of HER2 protein on H&E-stained tissue samples.*
Trained via orthogonal proteomic and gene expression methods, HER2Complete can identify HER2 expression in patients currently classified as IHC negative (or IHC-0), in addition to expression in HER2-low (IHC1+ and 2+/FISH negative) patients.
The Power of Paige
How Paige is able to leverage data from H&E for advanced AI algorithms
Paige’s access to millions of pathology images and corresponding clinical datasets has enabled us to build best-in-class detection algorithms for uncovering cancer features from H&E-stained whole slide images alone.
By identifying cytoarchitectural changes in tissue – across numerous tissue types – Paige is able to develop advanced AI algorithms that provide valuable insights that could empower oncologists to inform treatment decisions and clinical trial enrollment.
Paige algorithms are developed to identify phenotypic signatures in H&E images that related to biological underpinnings, including genotypic, prognostic and predictive features, to provide direct insight into tumor biology and enable precision oncology.
Future HER2 Assays
Ongoing Research and Development
Interested in HER2 AI assays?
Stay up to date on the latest HER2 research
2 Modi S, Jacot W, Yamashita T, et al; DESTINY-Breast04 Trial Investigators. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9-20.
*In the United States, the software is available for Research Use Only and not for use in diagnostic procedures.
